- Home
- CTRN vs DRUG Comparison
CTRN vs DRUG Comparison
Compare CTRN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- DRUG
- Stock Information
- Founded
- CTRN 1946
- DRUG 2019
- Country
- CTRN United States
- DRUG United States
- Employees
- CTRN N/A
- DRUG N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- DRUG Pharmaceuticals and Biotechnology
- Sector
- CTRN Consumer Discretionary
- DRUG Health Care
- Exchange
- CTRN Nasdaq
- DRUG Nasdaq
- Market Cap
- CTRN 280.0M
- DRUG 233.2M
- IPO Year
- CTRN 2005
- DRUG N/A
- Fundamental
- Price
- CTRN $29.22
- DRUG $27.31
- Analyst Decision
- CTRN Buy
- DRUG Strong Buy
- Analyst Count
- CTRN 2
- DRUG 6
- Target Price
- CTRN $24.50
- DRUG $83.25
- AVG Volume (30 Days)
- CTRN 132.6K
- DRUG 19.6K
- Earning Date
- CTRN 06-03-2025
- DRUG 08-13-2025
- Dividend Yield
- CTRN N/A
- DRUG N/A
- EPS Growth
- CTRN N/A
- DRUG N/A
- EPS
- CTRN N/A
- DRUG N/A
- Revenue
- CTRN $768,518,000.00
- DRUG N/A
- Revenue This Year
- CTRN $6.80
- DRUG N/A
- Revenue Next Year
- CTRN $4.61
- DRUG N/A
- P/E Ratio
- CTRN N/A
- DRUG N/A
- Revenue Growth
- CTRN 1.85
- DRUG N/A
- 52 Week Low
- CTRN $13.66
- DRUG $0.93
- 52 Week High
- CTRN $34.63
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- CTRN 51.47
- DRUG 41.95
- Support Level
- CTRN $32.03
- DRUG $27.69
- Resistance Level
- CTRN $30.43
- DRUG $28.74
- Average True Range (ATR)
- CTRN 1.48
- DRUG 1.29
- MACD
- CTRN -0.60
- DRUG 0.14
- Stochastic Oscillator
- CTRN 36.65
- DRUG 39.29
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.